Ocera Therapeutics Inc. (NASDAQ:OCRX) shares saw unusually-high trading volume on Friday . Approximately 77,347 shares traded hands during mid-day trading, an increase of 48% from the previous session’s volume of 52,183 shares.The stock last traded at $2.59 and had previously closed at $2.53.

A number of equities analysts have recently weighed in on OCRX shares. Zacks Investment Research cut shares of Ocera Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Brean Capital reaffirmed a “buy” rating on shares of Ocera Therapeutics in a research note on Tuesday, April 12th.

The firm has a 50-day moving average price of $2.30 and a 200-day moving average price of $2.75. The company’s market cap is $55.61 million.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. Equities analysts predict that Ocera Therapeutics Inc. will post ($1.39) earnings per share for the current year.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Turner Investments L.P. boosted its stake in Ocera Therapeutics Inc. (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 673,487 shares of the biopharmaceutical company’s stock after buying an additional 152,210 shares during the period. Turner Investments L.P. owned 3.28% of Ocera Therapeutics worth $2,101,000 as of its most recent SEC filing.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.